NKMAX Announces CAR-NK Cell Therapy Research Results at US SITC

NKMAX announced on the 3rd that its subsidiary NKGEN BIOTECH will present a research abstract as a poster at the Society for Immunotherapy of Cancer (SITC) conference to be held in November. The SITC conference will take place from November 3 to 5 in San Diego, California, USA.

The selected abstract presents research results on the anti-tumor effects of ‘HER2-CAR SNK02’ against HER2-expressing tumors. ‘HER2-CAR SNK02’ is a cell therapy product created by inserting the epithelial growth factor receptor (HER2) into NK cells from healthy donors. It targets HER2-overexpressing solid tumors such as breast cancer and gastric cancer, which have high incidence rates. When HER2 is overexpressed in cancer cells, they receive more growth factors, causing the cancer cells to grow faster.

In particular, ‘HER2-CAR SNK02’ has the advantage of excellent versatility due to NKMAX’s proprietary cryopreservation technology. Since freezing storage is essential for cell therapy products, the product maintains an activity level of over 90% after thawing for use, enabling long-term storage and administration.

An NKMAX representative stated, “Following the ASCO conference, we are honored to participate in the world’s most prestigious cancer conference and present our research results. This will be an opportunity to share the potential and efficacy of our gene-unmodified autologous NK cell therapy (SNK01) as well as the off-the-shelf form of HER2-CAR SNK02.”

This content was produced with the assistance of AI translation services.